PI-273 NEW
| Price | $38 | $77 | $133 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-15 |
Product Details
| Product Name: PI-273 | CAS No.: 925069-34-7 |
| Purity: 98.04% | Supply Ability: 10g |
| Release date: 2024/11/15 |
Product Introduction
Bioactivity
| 名稱 | PI-273 |
| 描述 | PI-273, a Substrate-Competitive, Specific Small-Molecule Inhibitor of PI4KIIα, Inhibits the Growth of Breast Cancer Cells |
| 體外活性 | PI-273 exhibited the greatest inhibitory effect on PI4KIIα kinase activity (IC50 = 0.47 μmol/L) and suppressed cell proliferation. Surface plasmon resonance and thermal shift assays indicated that PI-273 interacted directly with PI4KIIα. The kinetic analysis identified PI-273 as a reversible competitive inhibitor with respect to the substrate phosphatidylinositol (PI), which contrasted with most other PI kinase inhibitors that bind the ATP binding site. PI-273 reduced PI4P content, cell viability, and AKT signaling in wild-type MCF-7 cells, but not in PI4KIIα knockout MCF-7 cells, indicating that PI-273 is highly selective for PI4KIIα. Mutant analysis revealed the role of palmitoylation insertion in the selectivity of PI-273 for PI4KIIα. In addition, PI-273 treatment retarded cell proliferation by blocking cells in G2-M, inducing cell apoptosis and suppressing colony-forming ability. Importantly, PI-273 significantly inhibited MCF-7 cell-induced breast tumor growth without toxicity. PI-273 is the first substrate-competitive, a subtype-specific inhibitor of PI4KIIα, the use of which will facilitate evaluations of PI4KIIα as a cancer therapeutic target. |
| 體內(nèi)活性 | PI-273 (intraperitoneal injection; 25 mg/kg/day; 15 days) significantly reduces tumor volume and weight in MCF-7 xenografts [1]. PI-273 (0.5 mg/kg intravenously or 1.5 mg/kg intragastrically; 0.08-5 hours) has a half-life of 0.411 hours for intravenous administration and 1.321 hours for intragastric administration, with an absolute bioavailability of 5.1% [1]. |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 1 mg/mL, Sonication is recommended. |
| 關(guān)鍵字 | PI4K | Inhibitor | PI4 kinases | PI 273 | Apoptosis | inhibit | Phosphatidylinositol 4 kinases | PI273 | PI-273 |
| 相關(guān)產(chǎn)品 | Stavudine | 5-Fluorouracil | Acetylcysteine | Kaempferol | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin | Lidocaine hydrochloride |
| 相關(guān)庫 | 細胞凋亡化合物庫 | 經(jīng)典已知活性庫 | 激酶抑制劑庫 | 抗癌細胞代謝庫 | 抗氧化化合物庫 | 抑制劑庫 | 代謝化合物庫 | 抗衰老化合物庫 | 已知活性化合物庫 | 抗癌活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2580.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $0.00/25KG |
VIP6Y
|
QINGDAO JADE NEW MATERIAL TECNOLOGY CO.,LTD
|
2020-06-16 | |
| $34.00/2mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $38.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-15 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY